Medical History Recorded as Tenth HIV Remission Case is Confirmed in Oslo Patient Following Stem Cell Transplant

In a significant breakthrough for global medical science, the tenth clinical case of sustained HIV remission has been officially recorded following an allogeneic hematopoietic stem cell transplant. The case involves a 63-year-old man, now referred to as the "Oslo patient," who was first diagnosed with HIV in 2006. In 2017, his medical situation became more complex when he was diagnosed with an aggressive myelodysplastic syndrome, a specific and dangerous form of blood cancer. To combat the malignancy, he underwent a bone marrow transplant in 2020, which ultimately led to the extraordinary long-term control of his HIV infection.

A critical element in this successful outcome was the remarkable genetic compatibility of the donor, who was the patient's own older brother. Researchers at Oslo University Hospital discovered that the donor possessed the rare homozygous CCR5Δ32/Δ32 genetic mutation. This specific mutation effectively renders the CCR5 receptor protein non-functional; since this protein usually serves as the primary entry point for HIV-1 to invade CD4+ T-cells, its absence provides a natural resistance to the infection. Although the transplant procedure is notoriously high-risk, with mortality rates ranging between 10% and 20% during the first year, the patient was able to entirely stop his antiretroviral therapy (ART) two years after the surgery took place.

According to the findings published in the prestigious journal Nature Microbiology on April 13, 2026, there are currently no detectable traces of the virus in the patient's body, reinforcing the conclusion of a full remission. Dr. Anders Eyvind Myhre, the lead author of the study, reported a marked decrease in anti-HIV antibodies and the absence of any specific T-cell response to the virus, indicating that the patient's biological memory of the disease has been effectively cleared. A major scientific takeaway was the observation of "full chimerism," a state where the patient's immune system was entirely replaced by donor cells, extending from the bone marrow to the gut tissues, which are known to be common sites for latent HIV persistence.

The Oslo patient now joins an extremely short list of individuals who have reached a state of functional cure, a journey that began with the famous "Berlin patient" in 2009. While the CCR5Δ32/Δ32 mutation is found in roughly one percent of the Scandinavian population, medical experts—including those from the IciStem consortium—stress that stem cell transplantation remains a non-scalable solution for the millions of people living with HIV. The procedure's extreme invasiveness and the danger of complications, such as the graft-versus-host disease that the Oslo patient himself endured, make it unsuitable for general use. Instead, the focus of future scientific inquiry is to develop less invasive gene-editing strategies that can mimic the protective effects of the CCR5 mutation without the associated risks of major surgery.